| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9a9ee004fc7b6c2a406308f1f310081 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-906
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-907 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d72b5a2ca354a8411610d4e79b93384
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a99e2febd1747a4c8ed98d243070a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f20e48a28346816ef704216829bf7ad |
| publicationDate |
2015-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015017234-A1 |
| titleOfInvention |
Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages |
| abstract |
The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages. The allylamine active ingredient is prepared in an acidic environment; the acidic environment altering the physiochemical properties of the active ingredient resulting in the active ingredient having a positive charge. The positive charge and enhancers used in the formula allow for increased penetration of the active ingredient through skin and skin appendages. The positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species through the bead structure, thus stabilizes the positively charged active ingredient inside the bead by impeding the interaction of the positively charged active ingredient and the catalytic species, and thereby extending the shelf life of the positively charged active ingredient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018343479-A1 |
| priorityDate |
2007-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |